Skip to content

    Beta Drugs Ltd

    BETA
    Healthcare·7 Nov 2025
    Management Summary

    Beta Drugs Ltd reported a solid H1 FY26 with 13% revenue growth and 17% EBITDA growth, driven by strategic market entries and backward integration. Despite a slight dip in gross margins due to product mix and H1 growth being below annual targets, management expects a strong H2, particularly in exports, and is progressing on regulatory approvals and new product launches, including biosimilars.

    Highlights

    5
    • Revenue grew 13% YoY to ₹204 crores in H1 FY26, driven by strong performance in branded oncology and CDMO.

    • EBITDA increased 17% YoY to ₹47 crores, with margins expanding by 72 basis points to 23.08%.

    • PAT, excluding one-time interest on convertible debentures, rose 18% YoY to ₹28.71 crores.

    • Successfully completed COFAPRIS audit in Mexico and cleared INVIMA audit for injectables, paving the way for international expansion.

    • Acquired a new facility for backward integration, reducing dependency on the China market and strengthening DMFs.

    Concerns

    3
    • H1 FY26 revenue growth of 13% was below the company's stated annual target of 20-25%, attributed to tender seasonality and order processing delays.

    • Consolidated gross profit margins saw a 1.5% decline YoY, primarily due to product mix changes in the CDMO segment towards lower-margin products.

    • Europe approval for the cytotoxic suspension plant has been delayed, now expected in Q1 FY27 (Jan-Mar 2026).

    What Changed1

    vs Q4 FY26

    Guidance items21 → 11 (-10)

    Key financials

    Single quarter

    05 metrics
    1. 01Total Sales₹204 Cr+13%YoY
    2. 02EBITDA₹47 Cr+16.6%YoY
    3. 03EBITDA Margin23.1%+3.3%YoY
    4. 04PAT (excl. debenture interest)₹28.71 Cr+18.1%YoY
    5. 05PAT Margin (excl. debenture interest)14.1%+4.1%YoY

    Segment breakdown

    • CDMO₹79 Cr38.8%
    • Domestic Owned Brand (Oncology)₹60 Cr29.5%
    • International (Exports)₹43 Cr21.1%
    • API₹12.25 Cr6.0%
    • Dermatology₹9.25 Cr4.5%
    Donut· Share of Revenue

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    M&A

    Licensed Oncology Intermediate Plant

    acquisition · closed · Consideration ₹NaN (cash)

    Liquidity

    Liquidity disclosed

    Cash has gone out from the cash and cash equivalent side to the fixed assets. Management is keeping cash for new product development, inorganic growth, and biosimilar investments.

    Guidance & targets

    11
    CategoryTargetPriority
    Revenue
    Revenue Growth
    20-25%
    Medium
    Revenue
    Exports Revenue
    ₹100 crores
    High
    Profitability
    EBITDA Margins
    23-25%
    High
    Sales
    Derma Business Sales
    ₹30-50 crores
    Medium
    Market Share
    Italian Product Market Share
    ₹50-100 crores
    Medium
    Product Launch
    Biosimilars Launch
    3-4 years
    Medium
    Product Launch
    New Oncology NDDS Launches
    2
    High
    Capacity
    Intermediate Plant Commissioning
    6-8 months
    High
    Regulatory Filings
    Dossier Filings
    150+ doses
    High
    Regulatory Approval
    Europe Approval
    Q1 FY27 (Jan-Mar 2026)
    High
    Regulatory Approval
    NSE Main Board Migration
    within 10 days
    High

    What to watch in Q3 FY26

    5

    NSE Main Board Migration

    next quarter
    CurrentPrincipal approval received, expected within 10 days of Nov 7, 2025
    TargetMigration completed

    Why it matters

    Successful migration to the main board will enhance the company's visibility, liquidity, and investor confidence.

    Before we begin, I would like to share that today we have got a call from NSE and they have said that they will be giving principal approval to migrate to the main board. So maximum 10 days, we will be migrating on NSE's main board.

    Risks & concerns

    3
    RiskSeverity

    Production Challenges

    Bad rains across North India and two audits from Mexico and Colombia caused 15-20 days of production challenges in H1 FY26.Management acknowledged

    low

    Europe Approval Delays

    Europe approval for the cytotoxic suspension plant has been delayed, now expected in Q1 FY27 (Jan-Mar 2026).Management acknowledged

    medium

    H1 Growth Below Target

    H1 FY26 revenue growth of 13% was below the company's 20-25% annual target, attributed to tender seasonality and order processing delays.Management acknowledged

    medium

    Q&A highlights

    8

    “See, our gross margin on a consolidated level is 1.5% less than the last year. This is basically because of the product mix only. I mean, in CMO, some products are there which we cannot keep it constant every time. Some price erosion is there, something like that. So, it is just because of product mix.”

    Analyst questioned a 3% decline in gross profit margins, and management clarified it was a 1.5% consolidated decline due to product mix in the CDMO segment, specifically lower-margin Platin group products.

    asked by Aastha Jain

    2 min read6 chapters

    Detailed Narrative

    01

    H1 FY26 Financial Performance and Growth Drivers

    Beta Drugs Ltd reported a 13% year-on-year revenue growth, reaching ₹204 crores in H1 FY26, despite production challenges due to adverse weather and audits. EBITDA increased by 17% to ₹47 crores, with margins expanding by 72 basis points to 23.08% from 22.36% in H1 FY25. PAT, excluding one-time📎 interest on convertible debentures, grew 18% to ₹28.71 crores, reflecting improved profitability and a PAT margin of 14.10%.

    02

    Strategic Market Expansion and Product Development

    The company successfully completed a COFAPRIS audit in Mexico, filing 16 dossiers and planning 15 more, alongside clearing an INVIMA audit for injectables. Beta Drugs also secured approval for India's first NDDS of Methotrexate oral solution and initiated its first in-licensing deal for aesthetics fillers with an Italian company, targeting a ₹50-100 crore market share in 3-5 years from an estimated ₹1,000 crore market. The derma division itself grew 45% YoY and became profitable with ₹11.32 lakhs EBITDA.

    03

    Backward Integration and Capacity Enhancement

    To reduce dependency on China and strengthen its DMFs, Beta Drugs acquired a licensed oncology intermediate plant for ₹9.45 crores, with an additional ₹15-20 crores planned for build-up and machinery over the next 6-8 months. This acquisition, along with increased capacity at the Adley formulation plant, positions the company for enhanced production and entry into regulated markets. Total additions to fixed assets in H1 FY26 amounted to approximately ₹25 crores.

    04

    Segmental Performance and Future Outlook

    In H1 FY26, CDMO contributed 39% (₹79 crores) to total revenue, domestic owned brands 34% (₹60 crores), and exports 21% (₹43 crores). While H1 exports growth was 10%, management anticipates a significant acceleration in H2 FY26, targeting over ₹100 crores in exports due to tender seasonality. The company maintains its full-year revenue growth guidance of 20-25% and EBITDA margins of 23-25%, expecting strong H2 performance to compensate for the H1 growth of 13%.

    05

    Working Capital and Margin Dynamics

    The company experienced a marginal increase in working capital days (from 92 to 95) and receivables days (from 103 to 108), attributed to higher sales volumes. Consolidated gross profit margins saw a 1.5% decline YoY, primarily due to product mix shifts within the CDMO segment towards lower-margin Platin group products, which constitute less than 7% of overall revenue. However, overall EBITDA margins improved, and management expects this trend to continue, with standalone Beta margins improving as regulated market export sales commence.

    06

    Regulatory and Operational Updates

    Beta Drugs received principal approval from NSE to migrate to the main board within 10 days, enhancing its market visibility. The long-delayed Europe approval for its cytotoxic suspension plant is now expected in Q1 FY27 (Jan-Mar 2026), following audit confirmation by mid-December. The company is also actively exploring entry into the biosimilars segment, with launches anticipated in 3-4 years, and plans to file 150-plus doses in regulated markets over the next two years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.